Recombinant lysostaphin protects mice from methicillin-resistant staphylococcus aureus pneumonia

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chen, Chen ^a,b,c,d   Fan, Huahao ^a,e   Huang, Yong ^a   Peng, Fan ^a   Fan, Hang ^a   Yuan, Shoujun ^b   Tong, Yigang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSTAPHIN; VANCOMYCIN; ANTIINFECTIVE AGENT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRANULOCYTE; HISTOPATHOLOGY; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG INJURY; LUNG PARENCHYMA; LUNG WEIGHT; LYMPHOCYTE COUNT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOCYTE; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; RECTUM TEMPERATURE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BLOOD CELL COUNT; HUMAN; LUNG; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PATHOLOGY; PNEUMONIA, STAPHYLOCOCCAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD CELL COUNT; FEMALE; HUMANS; LUNG; LYSOSTAPHIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; PNEUMONIA, STAPHYLOCOCCAL; RECOMBINANT PROTEINS; VANCOMYCIN;

EID: 84929051849     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/602185     Document Type: Article

References (30)

1. H. F. L. Wertheim, D. C. Melles, M. C. Vos et al. , "The role of nasal carriage in Staphylococcus aureus infections, " The Lancet Infectious Diseases, vol. 5, no. 12, pp. 751-762, 2005.
2. F. D. Lowy, "Staphylococcus aureus infections, "TheNew England Journal of Medicine, vol. 339, no. 8, pp. 520-532, 1998.
3. H. Grundmann, M. Aires-de-Sousa, J. Boyce, and E. Tiemersma, "Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat, " The Lancet, vol. 368, no. 9538, pp. 874-885, 2006.
4. G. Lina, Y. Píemont, F. Godail-Gamot et al. , "Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia, " Clinical Infectious Diseases, vol. 29, no. 5, pp. 1128-1132, 1999.
5. J. S. Francis, M. C. Doherty, U. Lopatin et al. , "Severe community-onset pneumonia in healthy adults caused by methicillinresistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes, " Clinical Infectious Diseases, vol. 40, no. 1, pp. 100-107, 2005.
6. R. G. Wunderink, J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and M. H. Kollef, "Linezolid vs vancomycinanalysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia, " Chest, vol. 124, no. 5, pp. 1789-1797, 2003.
7. N. van de Sande-Bruinsma, H. Grundmann, D. Verloo et al. , "Antimicrobial drug use and resistance in Europe, " Emerging Infectious Diseases, vol. 14, no. 11, pp. 1722-1730, 2008.
8. S. E. Cosgrove, G. Sakoulas, E. N. Perencevich, M. J. Schwaber, A. W. Karchmer, and Y. Carmeli, "Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis, " Clinical Infectious Diseases, vol. 36, no. 1, pp. 53-59, 2003.
9. M. Melzer, S. J. Eykyn, W. R. Gransden, and S. Chinn, "Ismethicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus A comparative cohort study of British patients with nosocomial infection and bacteremia, " Clinical Infectious Diseases, vol. 37, no. 11, pp. 1453-1460, 2003.
10. S. Shurland, M. Zhan, D. D. Bradham, and M. C. Roghmann, "Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible staphylococcus aureus, " InfectionControl andHospital Epidemiology, vol. 28, no. 3, pp. 273-279, 2007.
11. Z. Athanassa, I. I. Siempos, and M. E. Falagas, "Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review, " European Respiratory Journal, vol. 31, no. 3, pp. 625-632, 2008.
12. W. Schaffner, M. Melly, J. Hash, and M. Koenig, "Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies, " Yale Journal of Biology and Medicine, vol. 39, no. 4, pp. 215-229, 1967.
13. V. T. Schuhardt and C. A. Schindler, "Lysostaphin therapy in mice infected with Staphylococcus aureus, " Journal of Bacteriology, vol. 88, pp. 815-816, 1964.
14. W. A. Zygmunt and P. A. Tavormina, "Lysostaphin: model for a specific enzymatic approach to infectious disease, " Progress in Drug Research, vol. 16, pp. 309-333, 1972.
15. M. R. Hanson and C. L. Chung, "Antibiotic selection for MRSA: case presentations and review of the literature, " Journal of Drugs in Dermatology, vol. 8, no. 3, pp. 281-286, 2009.
16. P. V. Adem, C. P. Montgomery, A. N. Husain et al. , "Staphylococcus aureus sepsis and theWaterhouse-Friderichsen syndrome in children, "The New England Journal ofMedicine, vol. 353, no. 12, pp. 1245-1251, 2005.
17. Y. Gillet, P. Vanhems, G. Lina et al. , "Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing panton-valentine leukocidin, " Clinical Infectious Diseases, vol. 45, no. 3, pp. 315-321, 2007.
18. F. Yang, "1th CMA Forum on Infection and Antimicrobial Chemotherapy, FIAC, " Chinese Journal of Infection and Chemotherapy, vol. 9, no. 6, pp. 479-480, 2011.
19. J. Aĺos, A. Garća-Cãnas, P. Garća-Hierro, and F. Rodŕguez-Salvańes, "Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage, " Journal of Antimicrobial Chemotherapy, vol. 62, no. 4, pp. 773-775, 2008.
20. A. Khosrovaneh, K. Riederer, S. Saeed et al. , "Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia, " Clinical Infectious Diseases, vol. 38, no. 9, pp. 1328-1330, 2004.
21. S. L. Gerson, S. L. Kaplan, J. B. Bruss et al. , "Hematologic effects of linezolid: summary of clinical experience, " Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, pp. 2723-2726, 2002.
22. J. J. Dajcs, E. B. H. Hume, J. M. Moreau, A. R. Caballero, B. M. Cannon, and R. J. OCallaghan, "Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit, " InvestigativeOphthalmology &Visual Science, vol. 41, no. 6, pp. 1432-1437, 2000.
23. J. J. Dajcs, B. A. Thibodeaux, D. O. Girgis, M. D. Shaffer, S. M. Delvisco, and R. J. OCallaghan, "Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit, " Investigative Ophthalmology and Visual Science, vol. 43, no. 12, pp. 3712-3716, 2002.
24. B. L. M. de Jonge, T. Sidow, Y.-S. Chang et al. , "Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus, " Journal of Bacteriology, vol. 175, no. 9, pp. 2779-2782, 1993.
25. K. Ehlert, M. Tschierske, C. Mori, W. Schroder, and B. Berger-Bachi, "Site-specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge, " Journal of Bacteriology, vol. 182, no. 9, pp. 2635-2638, 2000.
26. U. Kopp, M. Roos, J. Wecke, and H. Labischinski, "Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target?" Microbial Drug Resistance, vol. 2, no. 1, pp. 29-41, 1996.
27. H. Maidhof, B. Reinicke, P. Blumel, B. Berger-Bachi, and H. Labischinski, "femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains, " Journal of Bacteriology, vol. 173, no. 11, pp. 3507-3513, 1991.
28. A. M. Stranden, K. Ehlert, H. Labischinski, and B. Berger-BACHI, "Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillinresistant Staphylococcus aureus, " Journal of Bacteriology, vol. 179, no. 1, pp. 9-16, 1997.
29. C. Kusuma, A. Jadanova, T. Chanturiya, and J. F. Kokai-Kun, "Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo, " Antimicrobial Agents and Chemotherapy, vol. 51, no. 2, pp. 475-482, 2007.
30. J. K. Kumar, "Lysostaphin: an antistaphylococcal agent, " Applied Microbiology and Biotechnology, vol. 80, no. 4, pp. 555-561, 2008.